A retrospective study evaluating effect of baseline retinopathy status on efficacy of intravitreal ranibizumab therapy for diabetic macular oedema

Trial Profile

A retrospective study evaluating effect of baseline retinopathy status on efficacy of intravitreal ranibizumab therapy for diabetic macular oedema

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2018 New trial record
    • 01 Sep 2017 Primary end point (Change in Central Subfield Thickness between groups) has been met as peer the results published in the Eye
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top